Table 2 Opioid use characteristics of the study participants: all respondents and by CBD knowledge and use

Number of years living with OUD

N = (%)

N = (%)

N = (%)

N = (%)

7.342

.119

  < 1 year

11 (2%)

5 (1.9%)

4 (2.6%)

2 (1.6%)

  1–2 years

24 (4.4%)

12 (4.5%)

8 (5.2%)

4 (3.1%)

  2–5 years

68 (12.4%)

30 (11.2%)

14 (9.1%)

24 (18.6%)

  5–10 years

101 (18.4%)

47 (17.6%)

27 (17.5%)

27 (20.9%)

  > 10 years

346 (62.9%)

173 (64.8%)

101 (65.6%)

72 (55.8%)

Duration of treatment for opioid use disorder

N = (%)

N = (%)

N = (%)

N = (%)

5.510

.239

  < 1 year

70 (12.7%)

26 (9.7%)

27 (17.5%)

17 (13.2%)

  1–2 years

61 (11.1%)

22 (8.2%)

17 (11.0%)

22 (17.1%)

  2–5 years

113 (20.5%)

51 (19.1%)

31 (20.1%)

31 (24.0%)

  5–10 years

100 (18.2%)

46 (17.2%)

27 (17.5%)

27 (20.9%)

  > 10 years

206 (37.5%)

122 (45.7%)

52 (33.8%)

32 (24.8%)

Medication for opioid use disorder

N = (%)

N = (%)

N = (%)

N = (%)

.925

.630

  Methadone

504 (91.6%)

243 (91.0%)

144 (93.5%)

117 (90.7%)

  Buprenorphine

24 (4.4%)

14 (5.2%)

5 (3.2%)

5 (3.9%)

  Naltrexone

–

–

–

–

  No medication

22 (4.0%)

10 (3.7%)

5 (3.2%)

7 (5.4%)

Opioid drug use other than methadone or buprenorphine?

N = (%)

N = (%)

N = (%)

N = (%)

4.701

.319

  Daily

134 (24.4%)

58 (21.7%)

41 (26.6%)

35 (27.1%)

  Weekly

79 (14.4%)

37 (13.9%)

27 (17.5%)

15 (11.6%)

  Monthly

34 (6.2%)

19 (7.1%)

6 (3.9%)

9 (7.0%)

  Rarely

84 (15.3%)

28 (10.5%)

26 (16.9%)

30 (23.3%)

  Never

219 (39.8%)

125 (46.8%)

54 (35.1%)

40 (31.0%)